Response to Sunitinib Malate in Advanced Alveolar Soft Part Sarcoma
Why the study?
Does continuous sunitinib malate improve tumor response in patients with progressive metastatic Alveolar soft part sarcoma?
Population
5 patients with progressive metastatic Alveolar soft part sarcoma (ASPS)
Design
Case_series
Follow-up
up to 12 months
Authors
Discussion
Loading...
Member takes
Implication
May support sunitinib in refractory alveolar soft part sarcoma; hypothesis-generating and should not change practice.
Structured PICO
Does continuous sunitinib malate improve tumor response in patients with progressive metastatic Alveolar soft part sarcoma?
P
Population
5 patients with progressive metastatic Alveolar soft part sarcoma (ASPS)
I
Intervention
Continuous sunitinib malate 37.5 mg/d
O
Outcome
Tumor response evaluated by RECIST criteria and positron emission tomographysurrogate
Sunitinib malate may have antitumor activity in progressive metastatic alveolar soft part sarcoma, potentially mediated through PDGFR and RET pathways.
Cite This Study
Stacchiotti et al. (2009) studied this question.